Amplitude Surgical – Consolidated 9-month Sales of €73.5 Million, Down 1.8% at Constant Exchange Rates

Regulatory News:

Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME plans) (“Amplitude” or the “Group”), leading French player on the global surgical technology market for lower-limb orthopedics, announces its sales for the third quarter of its 2020-21 financial year.

Olivier Jallabert, Amplitude Surgical’s CEO, commented: “Amplitude Surgical’s activity is continuing to be impacted on most of its markets following the deterioration in the public health situation associated with COVID-19, and notably the adoption of restrictions on access to operating rooms. As a result, the Group’s activity was down by 1.8% at constant exchange rates compared with the same period last year, which saw an almost total shutdown in activity from mid-March 2020. During the first half of April 2021, we have observed an acceleration in the impact of the public health crisis, notably on our markets in France, Germany and Brazil. Novastep, meanwhile, is continuing its growth and now accounts for around 13% of the Group’s sales, with growth of almost 33% at constant exchange rates over the first 9 months of the year”.

Q3 2020-21 sales	31/03/2021	31/03/2020	Δ current exchange rates	Δ constant exchange rates
€ thousands - IFRS
France	18,775	17,721	5.9%	5.9%
International	8,827	8,895	-0.8%	2.1%
of which: Subsidiaries	6,758	6,253	8.1%	12.0%
of which: Distributors	2,068	2,641	-21.7%	-21.4%
Total	27,602	26,616	3.7%	4.7%